P225: Cross-sectional evaluation of transmural healing in patients with Crohn’s disease on maintenance treatment with biologicsECCO '16 Amsterdam
2016
P226: The first validated post-operative endoscopic Crohn’s disease index: the POCER index— identification of key endoscopic prognostic factorsECCO '16 Amsterdam
2016
P227: Faecal calprotectin reductions in patients achieving mucosal healing with vedolizumab induction therapy in GEMINI 1ECCO '16 Amsterdam
2016
P228: Prevalence of malnutrition and nutritional characteristics of patients with inflammatory bowel diseaseECCO '16 Amsterdam
2016
P229: Evidence of content validity and psychometric properties of SF-36 for measuring health-related quality of life of patients with Crohn’s diseaseECCO '16 Amsterdam
2016
P230: Elevated angiopoietins independent of TNF α regulation appear to play a key role in immune mediated angiogenesis in inflammatory bowel diseaseECCO '16 Amsterdam
2016
P231: Development of a small bowel capsule endoscopic index of severity in patients with Crohn’s diseaseECCO '16 Amsterdam
2016
P232: Paediatric Crohn’s disease and its disability over time: a study performed with a new paediatric Lemann Index: preliminary data from a tertiary Paediatric IBD centreECCO '16 Amsterdam
2016
P233: Management of patients with quiescent Crohn’s disease based on Capsule Endoscopy Crohn’s Disease Activity IndexECCO '16 Amsterdam
2016
P234: The diagnostic yield of small bowel capsule endoscopy in postsurgical Crohn’s diseaseECCO '16 Amsterdam
2016
P235: The association between serum vitamin D status and disease activity in paediatric inflammatory bowel diseaseECCO '16 Amsterdam
2016
P236: Faecal calprotectin is a poor predictor of irritable bowel disease relapse during pregnancyECCO '16 Amsterdam
2016
P237: Ionising radiation exposure in patients with Crohn´s disease: estimation and risk factorsECCO '16 Amsterdam
2016
P238: Vitamin D deficiency in inflammatory bowel disease: is malabsorption to blame?ECCO '16 Amsterdam
2016
P239: Hospitalisations and characteristics of patients with ulcerative colitis and Crohn’s disease treated with vedolizumab in real-world clinical practice: results from a multicentre studyECCO '16 Amsterdam
2016
P241: Risk factors associated with perianal Crohn’s disease in Korean childrenECCO '16 Amsterdam
2016
P242: Performance of the BÜHLMANN Quantum Blue® Infliximab point-of-care assay dedicated for therapeutic drug monitoring of serum infliximab trough levelsECCO '16 Amsterdam
2016